Alvotech and stada broaden access to hukyndra® adalimumab biosimilar in europe

Alvotech (nasdaq: alvo) and stada are contributing to the availability of high-quality biologic treatments in europe by rolling out their hukyndra high-concentration, low-volume, citrate-free formulation of adalimumab in several european countries.

ALVO Ratings Summary

ALVO Quant Ranking